Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 29
Filtrar
1.
Dig Dis Sci ; 66(12): 4557-4564, 2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-33537921

RESUMEN

Collagenous colitis (CC) is associated with non-bloody, watery diarrhea, which is pathophysiologically reasonable because normal colonic absorption (or excretion) of water and electrolytes can be blocked by the abnormally thick collagen layer in CC. However, CC has also been associated with six previous cases of protein-losing enteropathy (PLE), with no pathophysiologic explanation. The colon does not normally absorb (or excrete) amino acids/proteins, which is primarily the function of the small bowel. Collagenous duodenitis (CD) has not been associated with PLE. This work reports a novel case of CD (and CC) associated with PLE; a pathophysiologically reasonable mechanism for CD causing PLE (by the thick collagen layer of CD blocking normal intestinal amino acid absorption); and a novel association of PLE with severe COVID-19 infection (attributed to relative immunosuppression from hypoproteinemia, hypoalbuminemia, hypogammaglobulinemia, and malnutrition from PLE).


Asunto(s)
Aminoácidos/metabolismo , COVID-19/etiología , Colitis Colagenosa/complicaciones , Duodenitis/complicaciones , Duodeno/fisiopatología , Absorción Intestinal , Mucosa Intestinal/fisiopatología , Enteropatías Perdedoras de Proteínas/etiología , Anciano , COVID-19/diagnóstico , COVID-19/fisiopatología , Colitis Colagenosa/diagnóstico , Colitis Colagenosa/fisiopatología , Colitis Colagenosa/terapia , Duodenitis/diagnóstico , Duodenitis/fisiopatología , Duodenitis/terapia , Duodeno/metabolismo , Femenino , Fluidoterapia , Glucocorticoides/uso terapéutico , Humanos , Mucosa Intestinal/metabolismo , Estado Nutricional , Nutrición Parenteral Total , Enteropatías Perdedoras de Proteínas/diagnóstico , Enteropatías Perdedoras de Proteínas/fisiopatología , Enteropatías Perdedoras de Proteínas/terapia , Factores de Riesgo , Resultado del Tratamiento , Tratamiento Farmacológico de COVID-19
3.
Scand J Gastroenterol ; 55(12): 1454-1466, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33142068

RESUMEN

OBJECTIVES: Faecal microbiota transfer (FMT) consists of the infusion of donor faecal material into the intestine of patients with the aim to restore a disturbed gut microbiota. METHODS: In this pilot study (NCT03275467), the effect of three repeated FMTs (day 0, two weeks, four weeks) was studied and followed up for six months in nine collagenous colitis (CC) patients, using two stool donors. RESULTS: Five patients had an active disease at the time of baseline sampling. The primary endpoint (remission at six weeks, defined as <3 stools whereof <1 watery stool per day) was achieved by two of these patients, and by one at eight weeks. Overall, in all nine patients, FMT did not result in a significant reduction of watery stools, assessed by daily diary. However, diarrhoea (assessed by gastrointestinal symptom rating scale) was significantly improved at four (p = .038) and eight weeks (p = .038), indigestion at eight (p = .045) and 12 weeks (p = .006), disease-related worries at four (p = .027) and eight weeks (p = .027), and quality of life at six months (p = .009). FMT resulted in an increased number of lamina propria lymphocytes, possibly indicating an initial mucosal immune activation. No serious adverse events, no systemic effects, and no changes in faecal calprotectin and psychological symptoms were observed. CONCLUSIONS: FMT is able to improve symptoms in a yet undefined subset of CC patients. Further studies could help to characterise this subset and to understand if these results can be generalised to all microscopic colitis patients.


Asunto(s)
Colitis Colagenosa , Colitis Ulcerosa , Microbiota , Colitis Colagenosa/terapia , Heces , Humanos , Proyectos Piloto , Calidad de Vida
4.
Medicine (Baltimore) ; 99(35): e21920, 2020 Aug 28.
Artículo en Inglés | MEDLINE | ID: mdl-32871927

RESUMEN

INTRODUCTION: Collagen colitis (CC) is a microscopic colitis diagnosed by mucosal biopsy and is extremely rare in children. PATIENT CONCERNS: We reported a child with severe persistent diarrhea that could not be relieved with traditional diarrheal treatment. No abnormalities were found after multiple colonoscopies. DIAGNOSES: A significant increase in total IgE levels was found in the patient's blood. He had a history of mild chronic allergic rhinitis and slightly intermittent wheezing. However, we found that the child had a hyperallergic reaction to multiple respiratory antigens and had mild pulmonary dysfunction. Finally, colonoscopy with biopsy identified the diagnosis of CC. INTERVENTION: Considering that a respiratory allergic reaction was one of the causes of diarrhea, anti-allergic treatment was given to the child, and his severe diarrhea was soon relieved. Corticosteroid treatment was suggested to the patient, but his parents firmly refused steroid therapy. According to the patient's specific allergic reaction to mites, desensitization treatment was finally chosen for him. OUTCOMES: After 1 year of desensitization for dust mites, the patient's respiratory symptoms improved, total IgE levels decreased, autoantibodies declined, and diarrhea did not reoccur. Colonoscopy with biopsy showed a significant improvement in pathology. CONCLUSION: CC in children is rare, and childhood CC induced by a respiratory allergic reaction has not been previously reported. Therefore, this is a special case of CC in a patient who was cured with anti-allergy treatments and desensitization instead of steroid therapy.


Asunto(s)
Colitis Colagenosa/diagnóstico , Colitis Colagenosa/etiología , Diarrea/etiología , Hipersensibilidad Respiratoria/complicaciones , Antialérgicos/uso terapéutico , Biopsia , Niño , Enfermedad Crónica , Colitis Colagenosa/terapia , Colonoscopía , Desensibilización Inmunológica , Diarrea/terapia , Humanos , Masculino , Hipersensibilidad Respiratoria/terapia
5.
Hum Pathol ; 96: 87-95, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31698005

RESUMEN

Patients with inflammatory bowel disease (IBD) may occasionally present with lymphocytic colitis/collagenous colitis (LC/CC) either before or after the onset of IBD. Although a few reports have described a small number of such cases, the relationship between these 2 disorders is still unclear. We evaluated 27 patients with diagnosis of either ulcerative colitis (UC) or Crohn disease (CD) and LC/CC. Clinical, endoscopic, and pathological features were reviewed. Ten patients with initial diagnoses of LC (n = 2)/CC (n = 8) evolved into UC (n = 7) or CD (n = 3) after a median interval of 14 months (range, 2-44 months). Among these, 4 patients with LC/CC evolving into IBD also had recurrent CC in a quiescent phase of IBD. Seventeen patients with initial diagnosis of UC (n = 11) or CD (n = 6) developed LC (n = 6)/CC (n = 11) after a median interval of 108 months (range, 15-548 months). IBD patients with initial presentation of LC/CC were significantly older than those who developed LC/CC after onset of IBD (66.5 versus 34.0 years old, P = .001). The interval time between LC/CC to IBD was significantly shorter than that of IBD to LC/CC (14 versus 108 months, P = .007). Quiescent UC with superimposed CC was the most common pattern (n = 8). Patients with CD had shorter interval time to develop LC/CC than UC patients, although it was not statistically significant (60.5 versus 139 months, P = .14). Endoscopically, most patients that started with LC/CC had unremarkable findings, but 11 of 17 patients who developed LC/CC after IBD showed quiescent chronic colitis. Histologically, LC/CC patients with diagnosis of IBD, either before or after, more frequently show active inflammation. Chronicity was more commonly seen in biopsy of LC/CC patients with a history of IBD. Our study found that IBD patients with initial presentation of LC/CC tend to occur in older age, with shorter interval time and frequent active inflammation in initial LC/CC. These findings suggest that LC/CC may be a spectrum of IBD as the initial presentation in a subset of older IBD patients. On the other hand, IBD patients can develop LC/CC associated with chronic mucosal injury many years after the onset of IBD (typically with >10 years interval time while patients are in remission phase), for which these 2 processes seem unrelated to each other.


Asunto(s)
Colitis Colagenosa/patología , Colitis Linfocítica/patología , Colitis Ulcerosa/patología , Colon/patología , Enfermedad de Crohn/patología , Adulto , Anciano , Biopsia , Colitis Colagenosa/inmunología , Colitis Colagenosa/terapia , Colitis Linfocítica/inmunología , Colitis Linfocítica/terapia , Colitis Ulcerosa/inmunología , Colitis Ulcerosa/terapia , Colon/inmunología , Colonoscopía , Enfermedad de Crohn/inmunología , Enfermedad de Crohn/terapia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Pronóstico , Recurrencia , Inducción de Remisión , Factores de Tiempo , Adulto Joven
6.
J Pediatr Gastroenterol Nutr ; 67(3): 328-334, 2018 09.
Artículo en Inglés | MEDLINE | ID: mdl-29601434

RESUMEN

INTRODUCTION: Collagenous gastritis is a rare disease characterized by the subepithelial deposition of collagen bands. Two phenotypes of the disease have been described: a pediatric-onset and an adult-onset type. The adult-onset form is associated with collagenous colitis and autoimmune disorders. No effective treatment has been identified to date. OBJECTIVE: We aim to describe the clinical features and outcomes of patients in our cohort and provide a summary of published pediatric cases with collagenous gastritis and colitis reported to date to gather information that will contribute to improved knowledge of this rare condition. METHODS: A retrospective chart review of all patients with collagenous gastritis and/or colitis who were treated at the Royal Children's Hospital, Melbourne, was performed. A literature review was also conducted. RESULTS: A total of 12 cases of collagenous gastritis were reviewed. Three of 12 (25%) patients had associated collagenous colitis. The most common clinical presentation was iron deficiency anemia. Nine (75%) patients were followed up, and repeat endoscopies were performed in 8 (67%). Iron deficiency anemia resolved in all patients on oral iron supplementation. Histologic improvement was only identified in one patient with the adult phenotype who had been treated with oral corticosteroids and azathioprine. CONCLUSIONS: Collagenous gastritis is a rare condition in children. A small proportion of children develop features of the "'adult" phenotype at a very young age. Patients with collagenous gastritis require long-term follow-up and monitoring of their disease. Further randomized clinical trials are needed to establish an effective therapeutic strategy.


Asunto(s)
Colitis Colagenosa/diagnóstico , Colitis Colagenosa/terapia , Gastritis/diagnóstico , Gastritis/terapia , Adolescente , Biopsia , Niño , Preescolar , Colitis Colagenosa/fisiopatología , Colágeno , Dieta/métodos , Dieta Sin Gluten , Endoscopía Gastrointestinal/métodos , Femenino , Estudios de Seguimiento , Mucosa Gástrica/fisiopatología , Gastritis/fisiopatología , Humanos , Masculino , Inhibidores de la Bomba de Protones/uso terapéutico , Estudios Retrospectivos
7.
Intern Med ; 57(1): 37-41, 2018 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-29033425

RESUMEN

We herein describe a 69-year-old man suffering from chronic diarrhea caused by lansoprazole (LPZ)-induced collagenous colitis (CC) accompanied with protein-losing enteropathy (PLE), diagnosed by increased fecal alpha-1 antitrypsin clearance and the findings of leakage from the descending colon to the sigmoid colon on scintigraphy. MR enterocolonography (MREC) was also performed for differentiating digestive diseases, and inflamed findings were observed around the same portion as those on scintigraphy, suggesting that this region was responsible for protein loss in this case. The MREC findings improved after the cessation of LPZ, and hypoalbuminemia also improved simultaneously. This case suggests that MREC may be a new and useful diagnostic tool for CC with PLE.


Asunto(s)
Colitis Colagenosa/inducido químicamente , Colitis Colagenosa/terapia , Diarrea/inducido químicamente , Lansoprazol/efectos adversos , Enteropatías Perdedoras de Proteínas/diagnóstico por imagen , Enteropatías Perdedoras de Proteínas/terapia , Anciano , Colitis Colagenosa/diagnóstico por imagen , Diarrea/terapia , Humanos , Imagen por Resonancia Magnética , Masculino , Enteropatías Perdedoras de Proteínas/etiología , Enfermedades Raras/diagnóstico , Enfermedades Raras/terapia , Resultado del Tratamiento
8.
Cochrane Database Syst Rev ; 11: CD003575, 2017 11 11.
Artículo en Inglés | MEDLINE | ID: mdl-29127772

RESUMEN

BACKGROUND: Collagenous colitis is a cause of chronic diarrhea. This updated review was performed to identify therapies for collagenous colitis that have been assessed in randomized controlled trials (RCTs). OBJECTIVES: The primary objective was to assess the benefits and harms of treatments for collagenous colitis. SEARCH METHODS: We searched CENTRAL, the Cochrane IBD Group Specialized Register, MEDLINE and EMBASE from inception to 7 November 2016. SELECTION CRITERIA: We included RCTs comparing a therapy with placebo or active comparator for the treatment of active or quiescent collagenous colitis. DATA COLLECTION AND ANALYSIS: Data were independently extracted by two authors. The primary outcome was clinical response or maintenance of response as defined by the included studies. Secondary outcome measures included histological response, quality of life and the occurrence of adverse events. Risk ratios (RR) and 95% confidence intervals (CI) were calculated for dichotomous outcomes. The Cochrane risk of bias tool was used to assess bias. The overall quality of the evidence was assessed using the GRADE criteria. MAIN RESULTS: Twelve RCTs (476 participants) were included. These studies assessed bismuth subsalicylate, Boswellia serrata extract, mesalamine, cholestyramine, probiotics, prednisolone and budesonide therapy. Four studies were low risk of bias. One study assessing mesalamine and cholestyramine was judged to be high risk of bias due to no blinding. The other studies had an unclear risk of bias for random sequence generation (five studies) allocation concealment (six studies), blinding (one study), incomplete outcome data (one study) and selective outcome reporting (one study). Clinical response occurred in 100% (4/4) of patients who received bismuth subsalicylate (nine 262 mg tablets daily for 8 weeks) compared to 0% (0/5) of patients who received placebo (1 study; 9 participants; RR 10.80, 95% CI 0.75 to 155.93; GRADE = very low). Clinical response occurred in 44% (7/16) of patients who received Boswellia serrata extract (three 400 mg/day capsules for 8 weeks) compared to 27% (4/15) of patients who received placebo (1 study; 31 participants; RR 1.64, 95% CI 0.60 to 4.49; GRADE = low). Clinical response occurred in 80% (24/30) of budesonide patients compared to 44% (11/25) of mesalamine patients (1 study; 55 participants; RR 1.82, 95% CI 1.13 to 2.93; GRADE = low). Histological response was observed in 87% (26/30) of budesonide patients compared to 44% (11/25) of mesalamine patients (1 study, 55 participants; RR 1.97, 95% CI 1.24 to 3.13; GRADE = low). There was no difference between the two treatments with respect to adverse events (RR 0.69, 95% CI 0.43 to 1.10; GRADE = low), withdrawals due to adverse events (RR 0.09, 95% CI 0.01 to 1.65; GRADE = low) and serious adverse events (RR 0.12, 95% CI 0.01 to 2.21; GRADE = low). Clinical response occurred in 44% (11/25) of mesalamine patients (3 g/day) compared to 59% (22/37) of placebo patients (1 study; 62 participants; RR 0.74, 95% CI 0.44 to 1.24; GRADE = low). Histological response was observed in 44% (11/25) and 51% (19/37) of patients receiving mesalamine and placebo, respectively (1 study; 62 participants; RR 0.86, 95% CI 0.50 to 1.47; GRADE = low). There was no difference between the two treatments with respect to adverse events (RR 1.26, 95% CI 0.84 to 1.88; GRADE = low), withdrawals due to adverse events (RR 5.92, 95% CI 0.70 to 49.90; GRADE = low) and serious adverse events (RR 4.44, 95% CI 0.49 to 40.29; GRADE = low). Clinical response occurred in 63% (5/8) of prednisolone (50 mg/day for 2 weeks) patients compared to 0% (0/3) of placebo patients (1 study, 11 participants; RR 4.89, 95% CI 0.35 to 68.83; GRADE = very low). Clinical response occurred in 29% (6/21) of patients who received probiotics (2 capsules containing 0.5 x 1010 CFU each of L. acidophilus LA-5 and B. animalis subsp. lactis strain BB-12 twice daily for 12 weeks) compared to 13% (1/8) of placebo patients (1 study, 29 participants, RR 2.29, 95% CI 0.32 to 16.13; GRADE = very low). Clinical response occurred in 73% (8/11) of patients who received mesalamine (800 mg three times daily) compared to 100% (12/12) of patients who received mesalamine + cholestyramine (4 g daily) (1 study, 23 participants; RR 0.74, 95% CI 0.50 to 1.08; GRADE = very low). Clinical response occurred in 81% (38/47) of patients who received budesonide (9 mg daily in a tapering schedule for 6 to 8 weeks) compared to 17% (8/47) of placebo patients (3 studies; 94 participants; RR 4.56, 95% CI 2.43 to 8.55; GRADE = low). Histological response was higher in budesonide participants (72%, 34/47) compared to placebo (17%, 8/47) (RR 4.15, 95% CI 2.25 to 7.66; GRADE = low). Clinical response was maintained in 68% (57/84) of budesonide patients compared to 20% (18/88) of placebo patients (3 studies, 172 participants, RR 3.30 95% CI 2.13 to 5.09; GRADE = low). Histological response was maintained in 48% (19/40) of budesonide patients compared to 15% (6/40) of placebo patients (2 studies; 80 participants; RR 3.17, 95% CI 1.44 to 6.95; GRADE = very low). No difference was found between budesonide and placebo for adverse events (5 studies; 290 participants; RR 1.18, o95% CI 0.92 to 1.51; GRADE = low), withdrawals due to adverse events (5 studies, 290 participants; RR 0.97, 95% CI 0.43 to 2.17; GRADE = very low) or serious adverse events (4 studies, 175 participants; RR 1.11, 95% CI 0.15 to 8.01; GRADE = very low). Adverse effects reported in the budesonide studies include nausea, vomiting, neck pain, abdominal pain, excessive sweating and headache. Adverse effects reported in the mesalamine studies included nausea and skin rash. Adverse effects in the prednisolone study included abdominal pain, headache, sleep disturbance, mood change and weight gain. AUTHORS' CONCLUSIONS: Low quality evidence suggests that budesonide may be effective for inducing and maintaining clinical and histological response in patients with collagenous colitis. We are uncertain about the benefits and harms of therapy with bismuth subsalicylate, Boswellia serrata extract, mesalamine with or without cholestramine, prednisolone and probiotics. These agents and other therapies require further study.


Asunto(s)
Colitis Colagenosa/terapia , Diarrea/terapia , Bismuto/uso terapéutico , Boswellia/química , Budesonida/uso terapéutico , Resina de Colestiramina/uso terapéutico , Enfermedad Crónica , Colitis Colagenosa/complicaciones , Diarrea/etiología , Glucocorticoides/uso terapéutico , Humanos , Mesalamina/uso terapéutico , Compuestos Organometálicos/uso terapéutico , Extractos Vegetales/uso terapéutico , Prednisolona/uso terapéutico , Probióticos/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Salicilatos/uso terapéutico
9.
World J Gastroenterol ; 23(7): 1319-1324, 2017 Feb 21.
Artículo en Inglés | MEDLINE | ID: mdl-28275312

RESUMEN

One to six percent of patients with microscopic colitis are refractory to medical treatment. The effect of faecal microbiota transplantation (FMT) in active collagenous colitis (CC) has, to the best of our knowledge, never been reported before. Here, we report the effect of repeated FMT in a patient with CC. The patient presented with severe symptoms including profuse diarrhea and profound weight loss. Although she responded to budesonide in the beginning, she became gradually refractory to medical treatment, and was therefore treated with FMT. The patient remained in remission for 11 mo after the third faecal transplantation. The immunomodulatory effect of the therapy was evaluated using flow cytometry, which showed alterations in the profile of intraepithelial and lamina propria lymphocyte subsets after the second transplantation. Our observations indicate that FMT can have an effect in CC, which support the hypothesis that luminal factors, influencing the intestinal microbiota, are involved in the pathogenesis of CC.


Asunto(s)
Colitis Colagenosa/microbiología , Colitis Colagenosa/terapia , Trasplante de Microbiota Fecal , Linfocitos/citología , Anciano , Biopsia , Colitis Colagenosa/inmunología , Colitis Ulcerosa/terapia , Diarrea , Heces , Femenino , Citometría de Flujo , Humanos , Microbiota
10.
J Gastroenterol Hepatol ; 32(1): 120-127, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-27620860

RESUMEN

BACKGROUND: Collagenous sprue (CS) is a rare form of enteropathy that had been reported to be associated with celiac disease (CD) and collagenous colitis (CC). The aim of our study was to compare the clinical features, treatments, and outcomes of CS, CD, and CC. METHODS: All patients with histologic diagnosis of CS, CD, or CC with complete clinical data were extracted from our pathology database between 1990 and 2015. Demographic and clinical features were recorded along with treatments and outcomes. RESULTS: A total of 21 patients with CS were included. Overall CS patients were more symptomatic with 17 (81.0%) patients with diarrhea and 15 (71.4%) with unintentional weight loss. Positive celiac serology was noted in 5 (23.8%) CS patients. CS patients had higher rates for disease-related temporary total parenteral nutrition (TPN) use (38.1% vs. 1.1% vs. 1.0%, P < 0.0001) and disease-related hospitalization (52.4% vs. 3.3% vs. 8.2%, P < 0.0001) than that in CD and CC patients. Twenty CS patients received treatments, including the combination of gluten-free diet (GFD) and corticosteroids (n = 12), GFD only (n = 2), and corticosteroids only (n = 6). All CS patients showed symptomatic reliefs with treatment. Although CS patients had a higher rate for hospitalization and TPN use, disease-related death was not observed in all three groups. CONCLUSIONS: Collagenous sprue patients had more severe clinical presentation than patients with CD and CC and therefore had higher demand for temporary TPN and hospitalization. Nevertheless, a prompt use of steroids and/or GFD upon histologic diagnosis of CS may have contributed to an overall excellent prognosis.


Asunto(s)
Enfermedad Celíaca , Colitis Colagenosa , Esprue Colágeno , Corticoesteroides/uso terapéutico , Anciano , Enfermedad Celíaca/terapia , Colitis Colagenosa/terapia , Esprue Colágeno/terapia , Diarrea , Dieta Sin Gluten , Femenino , Hospitalización/estadística & datos numéricos , Humanos , Masculino , Persona de Mediana Edad , Nutrición Parenteral Total/estadística & datos numéricos , Pronóstico , Pérdida de Peso
12.
Ann Med ; 46(5): 311-7, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24716737

RESUMEN

AIM: While collagenous colitis represents the most common form of the collagenous gastroenteritides, the collagenous entities affecting the proximal part of the gastrointestinal tract are much less recognized and possibly overlooked. The aim was to summarize the latest information through a systematic review of collagenous gastritis, collagenous sprue, and a combination thereof. METHOD: The search yielded 117 studies which were suitable for inclusion in the systematic review. Excluding repeated cases, 89 case reports and 28 case series were reported, whereas no prospective studies with or without control groups were identified. Further, no randomized, controlled trials were identified. The total number of patients with proximal collagenous gastroenteritides reported was 330. RESULTS: An overview of clinical presentations, prognosis, pathophysiology and histopathology, as well as management of these disorders is presented. The prognosis of both collagenous gastritis and sprue seems not to be as dismal as considered previously. Data point to involvement of immune or autoimmune mechanisms potentially driven by luminal antigens initiating the fibroinflammatory condition. CONCLUSIONS: To reach the diagnosis it is recommended that biopsies are obtained during gastroduodenoscopies. Therapies with anti-secretory strategies, glucocorticoids, and in some cases iron supplementation are suggested, although rational treatment options from randomized, controlled trials do not exist for these rare or even overlooked disorders.


Asunto(s)
Colitis Colagenosa/fisiopatología , Esprue Colágeno/fisiopatología , Gastroenteritis/fisiopatología , Biopsia , Colitis Colagenosa/diagnóstico , Colitis Colagenosa/terapia , Colágeno/metabolismo , Esprue Colágeno/diagnóstico , Esprue Colágeno/terapia , Endoscopía Gastrointestinal/métodos , Gastritis/diagnóstico , Gastritis/fisiopatología , Gastritis/terapia , Gastroenteritis/diagnóstico , Gastroenteritis/terapia , Glucocorticoides/uso terapéutico , Humanos , Compuestos de Hierro/uso terapéutico , Pronóstico
13.
World J Gastroenterol ; 19(26): 4252-6, 2013 Jul 14.
Artículo en Inglés | MEDLINE | ID: mdl-23864791

RESUMEN

Lymphocytic and collagenous colitis are forms of microscopic colitis which typically presents in elderly patients as chronic watery diarrhea. The association between microscopic colitis and inflammatory bowel disease is weak and unclear. Lymphocytic colitis progressing to ulcerative colitis has been previously reported; however there is limited data on ulcerative colitis evolving into microscopic (lymphocytic or collagenous) colitis. We report a series of six patients with documented ulcerative colitis who subsequently were diagnosed with collagenous colitis or lymphocytic colitis suggesting microscopic colitis could be a part of the spectrum of inflammatory bowel disease. The median duration of ulcerative colitis prior to being diagnosed with microscopic colitis was 15 years. We noted complete histological and/or symptomatic remission in three out of six cases while the other three patients reverted back into ulcerative colitis suggesting lymphocytic or collagenous colitis could present as a continuum of ulcerative colitis. The exact molecular mechanism of this histological transformation or the prognostic implications is still unclear. Till then it might be prudent to follow up these patients to assess for the relapse of inflammatory bowel disease as well as for dysplasia surveillance.


Asunto(s)
Colitis Colagenosa/diagnóstico , Colitis Linfocítica/diagnóstico , Colitis Ulcerosa/diagnóstico , Colon/patología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Biopsia , Colitis Colagenosa/clasificación , Colitis Colagenosa/patología , Colitis Colagenosa/terapia , Colitis Linfocítica/clasificación , Colitis Linfocítica/patología , Colitis Linfocítica/terapia , Colitis Ulcerosa/clasificación , Colitis Ulcerosa/patología , Colitis Ulcerosa/terapia , Colonoscopía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Recurrencia , Inducción de Remisión , Factores de Tiempo , Resultado del Tratamiento
14.
Intern Med ; 52(11): 1183-7, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23728552

RESUMEN

A 63-year-old woman was admitted with symptoms of watery diarrhea and generalized edema lasting for five months. She had been administered 15 mg/day of lansoprazole. Laboratory findings revealed severe hypoproteinemia with normal liver, renal, thyroid and adrenal functions and no proteinuria. Colonoscopy revealed edematous mucosa, minor diminished vascular transparency and apparent longitudinal linear lacerations. The histopathological findings were compatible with a diagnosis of collagenous colitis (CC). Protein leakage from the colon was identified on (99m)Tc-human serum albumin scintigraphy. The results indicated CC associated with protein-losing enteropathy. Discontinuing lansoprazole ameliorated the watery diarrhea and generalized edema, increased the serum albumin level and improved the hypoproteinemia.


Asunto(s)
Colitis Colagenosa/inducido químicamente , Colitis Colagenosa/diagnóstico , Enteropatías Perdedoras de Proteínas/inducido químicamente , Enteropatías Perdedoras de Proteínas/diagnóstico , Inhibidores de la Bomba de Protones/efectos adversos , Privación de Tratamiento , Colitis Colagenosa/terapia , Femenino , Humanos , Persona de Mediana Edad , Enteropatías Perdedoras de Proteínas/terapia
15.
Inflamm Bowel Dis ; 19(7): 1470-6, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23552765

RESUMEN

BACKGROUND: Whether current smoking worsens the clinical course of microscopic colitis (MC) is unknown. The aim was to evaluate the impact of smoking on the clinical course of MC. METHODS: One hundred and eighty-four patients (72% women; age, 62.4 ± 1.1 years) with MC (118 collagenous colitis (CC) and 66 lymphocytic colitis (LC) were evaluated (39 of them were current smokers). In all the patients, smoking habits and clinical data at presentation, response to therapy, and clinical relapses during follow-up were prospectively recorded. Risk factors for clinical relapse were studied in 160 patients after a mean follow-up of 28 ± 1 months. Cox regression analysis was used to adjust for confounding variables. RESULTS: Age at diarrhea onset was 63.0 ± 1.4 years in nonsmokers and 50.4 ± 2.1 years in current smokers (P < 0.001). There was no significant influence of smoking habit on either clinical symptoms at diagnosis or clinical remission rate. Clinical relapse rate was 25.5% for CC and 29.6% for LC, with the mean relapse-free time 28.8 months (95% confidence interval, 26.3-31.4) for CC and 26.9 months (95% confidence interval, 26-30.3) for LC (P = 0.5). Multivariate analysis showed that age at diagnosis (<50 years versus others; adjusted hazard ratio, 2.8; 95% confidence interval, 1.3-6; P = 0.01) was associated with risk of relapse of CC but not LC. Current smoking was not an independent risk factor for either CC or LC relapse. CONCLUSIONS: Active smokers developed MC more than a decade before nonsmokers. Age at diagnosis, but not smoking, was an independent risk factor of relapse in patients with CC.


Asunto(s)
Colitis Colagenosa/etiología , Colitis Linfocítica/etiología , Colitis Microscópica/etiología , Fumar/efectos adversos , Anciano , Colitis Colagenosa/patología , Colitis Colagenosa/terapia , Colitis Linfocítica/patología , Colitis Linfocítica/terapia , Colitis Microscópica/patología , Colitis Microscópica/terapia , Colonoscopía , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Prospectivos , Recurrencia , Factores de Riesgo
16.
Can J Gastroenterol ; 26(9): 627-30, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22993735

RESUMEN

Microscopic forms of colitis have been described, including collagenous colitis, a possibly heterogeneous disorder. Collagenous colitis most often appears to have an entirely benign clinical course that usually responds to limited treatment. Sometimes significant extracolonic disorders, especially arthritis, spondylitis, thyroiditis and skin disorders, such as pyoderma gangrenosum, dominate the clinical course and influence the treatment strategy. However, rare fatalities have been reported and several complications, some severe, have been attributed directly to the colitis. Toxic colitis and toxic megacolon may develop. Concomitant gastric and small intestinal inflammatory disorders have been described including celiac disease and more extensive collagenous inflammatory disease. Colonic ulceration has been associated with the use of nonsteroidal anti-inflammatory drugs, while other forms of inflammatory bowel disease, including ulcerative colitis and Crohn disease, may evolve directly from collagenous colitis. Submucosal 'dissection', colonic fractures, or mucosal tears and perforation, possibly from air insufflation during colonoscopy, have been reported. Similar changes may result from increased intraluminal pressures that may occur during radiological imaging of the colon. Neoplastic disorders of the colon may also occur during the course of collagenous colitis, including colon carcinoma and neuroendocrine tumours (ie, carcinoids). Finally, lymphoproliferative disease has been reported.


Asunto(s)
Colitis Colagenosa/etiología , Colitis Colagenosa/patología , Colitis Colagenosa/terapia , Colonoscopía , Humanos
17.
Best Pract Res Clin Gastroenterol ; 26(5): 611-22, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23384806

RESUMEN

Microscopic colitis includes the terms lymphocytic colitis and collagenous colitis, and is a common cause of chronic diarrhoea in older adults. The incidence of microscopic colitis has increased over time and has reached levels comparable to other forms of inflammatory bowel disease. In this chapter, an updated review on the epidemiology, diagnosis and treatment of microscopic colitis has been provided. There is limited data available about eosinophilic colitis, which is the least common of the eosinophilic GI disorders. It is important to rule out the secondary causes of colonic eosinophilia in patients with suspected eosinophilic colitis.


Asunto(s)
Colitis Microscópica/complicaciones , Diarrea/etiología , Enfermedad Crónica , Colitis Colagenosa/complicaciones , Colitis Colagenosa/diagnóstico , Colitis Colagenosa/epidemiología , Colitis Colagenosa/terapia , Colitis Linfocítica/complicaciones , Colitis Linfocítica/diagnóstico , Colitis Linfocítica/epidemiología , Colitis Linfocítica/terapia , Colitis Microscópica/diagnóstico , Colitis Microscópica/epidemiología , Colitis Microscópica/terapia , Diarrea/epidemiología , Humanos , Incidencia , Enfermedades Inflamatorias del Intestino/complicaciones , Síndrome del Colon Irritable/complicaciones
20.
Eur J Intern Med ; 20(5): 499-502, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19712853

RESUMEN

INTRODUCTION: Collagenous colitis can be the cause of chronic diarrhoea. AIM: Assess the prevalence of collagenous colitis in a single centre. PATIENTS: All records of patients with diarrhoea in whom histological examination showed collagenous colitis, were retrieved. Demographic data, clinical presentation, associated diseases and treatment were studied. RESULTS: In a period of 15 years 83 patients were identified with collagenous colitis. These were 16 men and 67 women, mean age 60 years (range 20-87) at time of diagnosis. Thirty four patients (38%) complained of mushy stools and 49 (62%) of watery diarrhoea. Eight patients had rectal bleeding. Mucous discharge was noted by 18 patients. There was no weight loss in 55 patients. Six patients complained of loss of appetite, 9 had nausea, and 2 complained of vomitus. A macroscopically normal colon was present in 63 patients. Associated diseases, like celiac disease and hypothyroidism, only were seen in women. Twenty eight patients did not receive any treatment, ten patients received mesalazine. One patient was treated with steroids. Fourteen patients were treated for accompanying bacterial overgrowth. Fourteen patients used loperamide. Budesonide was applied with success in 17 patients. During follow-up 58 patients had no complaints anymore, 21 had mild diarrhoea, 3 moderate, while it was unknown in one patient. CONCLUSION: Collagenous colitis has a higher prevalence as usually reported. There is an association with auto-immune disorders and dysbacteriosis.


Asunto(s)
Colitis Colagenosa/complicaciones , Colitis Colagenosa/patología , Adulto , Anciano , Anciano de 80 o más Años , Antiinflamatorios/uso terapéutico , Antidiarreicos/uso terapéutico , Colitis Colagenosa/terapia , Colonoscopía , Estudios Transversales , Diarrea/etiología , Diarrea/patología , Diarrea/terapia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Resultado del Tratamiento , Pérdida de Peso , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA